Perspective from Carlos del Rio, MD
May 10, 2019
2 min read
Save

Gilead agrees to donate HIV PrEP for up to 200K people a year

Perspective from Carlos del Rio, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Gilead Sciences has agreed to donate free pre-exposure prophylaxis, or PrEP, for HIV prevention for up to 200,000 individuals each year for up to 11 years, HHS announced.

The agreement between HHS and Gilead will last through Dec. 31, 2025, and possibly through Dec. 31, 2030, and will provide Gilead’s PrEP medication Truvada (emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) to uninsured individuals who are at risk for HIV, HHS said.

Truvada, which costs approximately $20,000 per patient per year, will be continuously donated until Gilead’s second-generation HIV preventive medication, Descovy (FTC/tenofovir alafenamide), becomes available, the department said.

HHS told Infectious Disease News that the donation program will focus on underserved, high-risk, and low-income areas. Individuals interested in receiving donated PrEP should go to a Federally Qualified Health Center with their basic information, including their name, date of birth and the last four digits of their Social Security numbers.

PrEP pill 
Gilead will donate Truvada for 200,000 uninsured people.
Source: Adobe Stock

“If they are uninsured and medically qualify for a prescription, they will be provided with a paper or electronic verification that they can then use at their local pharmacy or mail-order pharmacy to get Truvada or Descovy at no cost to them,” the department told Infectious Disease News.

Increasing the use of PrEP is a focus of the Trump administration’s plan to end the HIV epidemic in the United States in 10 years, which was announced in President Donald J. Trump’s second State of the Union Address. The plan aims to reduce new HIV infections in the U.S. by 75% in 5 years and by 90% by 2030.

Taken consistently, PrEP has been shown to reduce the risk for HIV infection by up to 92%, according to the CDC. The agency has said in the past that more than 1.1 million adults in the U.S. meet indications for HIV PrEP.

Gilead, which has faced criticism over the price of the medication, announced this week that a generic version of FTC/TDF would be available in 2020, a year earlier than expected.

“Securing this commitment is a major step in the Trump administration’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030,” HHS Secretary Alex M. Azar said in a statement about the donation plan.

“Under President Trump’s leadership, HHS worked with Gilead to secure preventive medication for individuals who might otherwise not be able to access or afford this important treatment. The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication. This agreement will help close that gap substantially and deliver on President Trump’s promise to end the HIV epidemic in America.” – by Caitlyn Stulpin

Reference:

HHS. Trump administration secures historic donation of billions of dollars in HIV prevention drugs. https://www.hhs.gov/about/news/2019/05/09/trump-administration-secures-historic-donation-of-billions-of-dollars-in-hiv-prevention-drugs.html. Accessed May 10, 2019.

Disclosure: Azar reports no relevant financial disclosures.